BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YESAFILI (aflibercept-jbvf) is a biosimilar fusion protein approved by the FDA in May 2024 as a Biocon product. It is administered via injection and represents a fusion modality therapeutic in the growth lifecycle stage. The specific indications and mechanism of action are not yet fully detailed in available sources.
Growth
Early-stage growth product with moderate competitive pressure (30%) suggests expanding commercial team and field-building opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YESAFILI represents a growth-stage biosimilar opportunity with emerging commercial demand. Working on this product offers early-career involvement in building market share and establishing a new biosimilar franchise for Biocon in the injectable fusion protein space.
Director
Commercial
Worked on YESAFILI at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.